Summary
43.91 0.63(1.44%)09/27/2024
Corcept Therapeutics Inc (CORT)
Corcept Therapeutics Inc (CORT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.44 | 3.94 | 26.75 | 37.03 | 73.26 | 35.63 | 201.13 | 258.99 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 43.91 | |
| Open | 43.22 | |
| High | 44.02 | |
| Low | 42.81 | |
| Volume | 458,117 | |
| Change | 0.63 | |
| Change % | 1.44 | |
| Avg Volume (20 Days) | 640,532 | |
| Volume/Avg Volume (20 Days) Ratio | 0.72 | |
| 52 Week Range | 20.84 - 44.37 | |
| Price vs 52 Week High | -1.05% | |
| Price vs 52 Week Low | 110.68% | |
| Range | 1.58 | |
| Gap Up/Down | -0.40 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,522 | |
| EBIDTA | 122,800,000 | |
| PE Ratio | 25.7524 | |
| PEG Ratio | 0.6100 | |
| WallStreet Target Price | 43.60 | |
| Book Value | 5.2670 | |
| Earnings Per Share | 1.0500 | |
| EPS Estimate Current Quarter | 0.2200 | |
| EPS Estimate Next Quarter | 0.2300 | |
| EPS Estimate Current Year | 0.9600 | |
| EPS Estimate Next Year | 1.2900 | |
| Diluted EPS (TTM) | 1.0500 | |
| Revenues | ||
| Profit Marging | 0.2254 | |
| Operating Marging (TTM) | 0.2009 | |
| Return on asset (TTM) | 0.1197 | |
| Return on equity (TTM) | 0.2191 | |
| Revenue TTM | 523,528,992 | |
| Revenue per share TTM | 5.1180 | |
| Quarterly Revenue Growth (YOY) | 0.3900 | |
| Quarterly Earnings Growth (YOY) | 0.7860 | |
| Gross Profit (TTM) | 396,473,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 25.7524 | |
| Forward PE | 71.4286 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.8158 | |
| Revenue Enterprise Value | 4.2956 | |
| EBITDA Enterprise Value | 18.8985 | |
| Shares | ||
| Shares Outstanding | 104,112,000 | |
| Shares Float | 85,361,501 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.27 | |
| Insider (%) | 11.38 | |
| Institutions (%) | 86.11 | |
09/19 12:54 EST - seekingalpha.com
3 Small Biotech Stocks With The 'Big Mo' Right Now
Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the paragraphs below.
3 Small Biotech Stocks With The 'Big Mo' Right Now
Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the paragraphs below.
09/19 08:55 EST - zacks.com
Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
09/15 11:40 EST - seekingalpha.com
Corcept Therapeutics - Three Dynamic Catalysts To Reaccelerate Growth
Corcept is a profitable midcap biotechnology company specializing in treating Cushing's Syndrome, with significant potential for revenue growth and expansion into other therapeutic areas. Recent study suggests Cushing's Syndrome is more prevalent than believed, leading to a significant expansion of its potential patient base. Corcept has developed Relacorilant as a far safer and more effective drug than its current drug Korlym for Cushing's which has just gone generic.
Corcept Therapeutics - Three Dynamic Catalysts To Reaccelerate Growth
Corcept is a profitable midcap biotechnology company specializing in treating Cushing's Syndrome, with significant potential for revenue growth and expansion into other therapeutic areas. Recent study suggests Cushing's Syndrome is more prevalent than believed, leading to a significant expansion of its potential patient base. Corcept has developed Relacorilant as a far safer and more effective drug than its current drug Korlym for Cushing's which has just gone generic.
09/03 12:32 EST - zacks.com
Corcept Shares Rise More Than 45% in Six Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.
Corcept Shares Rise More Than 45% in Six Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.
08/27 13:01 EST - zacks.com
Corcept (CORT) Upgraded to Buy: Here's Why
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Corcept (CORT) Upgraded to Buy: Here's Why
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
08/26 10:00 EST - prnewswire.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT)
NEW YORK , Aug. 26, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of the company's shareholders. The investigation seeks to determine whether Corcept's directors breached their fiduciary duties in connection with recent corporate actions.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT)
NEW YORK , Aug. 26, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of the company's shareholders. The investigation seeks to determine whether Corcept's directors breached their fiduciary duties in connection with recent corporate actions.
08/16 10:55 EST - zacks.com
Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade
The consensus price target hints at a 70.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade
The consensus price target hints at a 70.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
08/16 09:20 EST - zacks.com
5 Small Drug Stocks to Buy as Innovation Reaches Peak
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
5 Small Drug Stocks to Buy as Innovation Reaches Peak
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
08/01 10:15 EST - zacks.com
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
07/31 13:20 EST - zacks.com
Can Corcept (CORT) Run Higher on Rising Earnings Estimates?
Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Corcept (CORT) Run Higher on Rising Earnings Estimates?
Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
07/31 13:01 EST - zacks.com
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
07/31 10:56 EST - zacks.com
Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?
The consensus price target hints at a 37.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?
The consensus price target hints at a 37.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
07/30 14:36 EST - seekingalpha.com
Corcept Therapeutics: Q2 Gains Overshadowed By Generic Competition And Speculative Pipeline
Corcept Therapeutics' strong Q2 earnings exceed expectations, with revenue climbing 39% YoY and EPS beating analyst estimates. The District Court ruled in favor of Teva, enabling the launch of a generic Korlym, which threatens Corcept's revenue. Corcept faces a lawsuit accusing it of antitrust behavior and alleged illicit bribes.
Corcept Therapeutics: Q2 Gains Overshadowed By Generic Competition And Speculative Pipeline
Corcept Therapeutics' strong Q2 earnings exceed expectations, with revenue climbing 39% YoY and EPS beating analyst estimates. The District Court ruled in favor of Teva, enabling the launch of a generic Korlym, which threatens Corcept's revenue. Corcept faces a lawsuit accusing it of antitrust behavior and alleged illicit bribes.
07/30 11:45 EST - zacks.com
Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates
Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.
Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates
Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.
07/29 21:22 EST - seekingalpha.com
Corcept Therapeutics Incorporated (CORT) Q2 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2024 Earnings Conference Call July 29, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charles Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer, President and Director Sean Maduck - President of Endocrinology William Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann & Co. David Amsellem - Piper Sandler & Co. Swayampakula Ramakanth - H.C. Wainwright Joon Lee - Truist Operator Hello.
Corcept Therapeutics Incorporated (CORT) Q2 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2024 Earnings Conference Call July 29, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charles Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer, President and Director Sean Maduck - President of Endocrinology William Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann & Co. David Amsellem - Piper Sandler & Co. Swayampakula Ramakanth - H.C. Wainwright Joon Lee - Truist Operator Hello.
07/29 18:56 EST - zacks.com
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.25 per share a year ago.
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.25 per share a year ago.
07/22 16:05 EST - globenewswire.com
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
07/18 09:10 EST - zacks.com
Navigate Market Turbulence With These 4 Low-Beta Stocks
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Cool Company (CLCO), Corcept Therapeutics (CORT), TXO Partners (TXO), & JOYY (YY) are well-poised to gain.
Navigate Market Turbulence With These 4 Low-Beta Stocks
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Cool Company (CLCO), Corcept Therapeutics (CORT), TXO Partners (TXO), & JOYY (YY) are well-poised to gain.
07/17 08:01 EST - zacks.com
5 Stocks With Recent Price Strength to Tap Wall Street Rally
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.
07/16 09:51 EST - zacks.com
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.